2023-09-20
Immutep S.A.S.
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use immutep.com ↗
2023-06-27
Immutep S.A.S.
Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor immutep.com ↗
2023-05-15
Immutep S.A.S.
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer immutep.com ↗
2023-05-02
Immutep S.A.S.
Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma immutep.com ↗
2023-04-30
Immutep S.A.S.
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO® immutep.com ↗
2023-03-13
Immutep S.A.S.
Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer immutep.com ↗
2022-12-22
Immutep S.A.S.
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer immutep.com ↗
2022-12-07
Immutep S.A.S.
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha immutep.com ↗
2022-11-28
Immutep S.A.S.
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer immutep.com ↗
2022-11-09
Immutep S.A.S.
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination immutep.com ↗
2022-11-09
Immutep S.A.S.
Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting immutep.com ↗
2022-11-03
Immutep S.A.S.
Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference immutep.com ↗
2022-11-01
Immutep S.A.S.
Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting immutep.com ↗
2022-10-03
Immutep S.A.S.
Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer immutep.com ↗
2022-09-13
Immutep S.A.S.
Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha immutep.com ↗
2022-09-05
Immutep S.A.S.
Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma immutep.com ↗
2022-08-29
Immutep S.A.S.
Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor immutep.com ↗
2022-07-31
Immutep S.A.S.
Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd line PD-X Refractory NSCLC immutep.com ↗
2022-02-11
Immutep S.A.S.
Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor immutep.com ↗
2021-11-19
Immutep S.A.S.
Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha immutep.com ↗
2021-11-14
Immutep S.A.S.
Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha immutep.com ↗
2021-11-14
Immutep S.A.S.
Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor immutep.com ↗
2021-11-02
Immutep S.A.S.
Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy Agent immutep.com ↗
2021-06-02
Immutep S.A.S.
Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor immutep.com ↗
2021-05-26
Immutep S.A.S.
Immutep Granted Chinese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination immutep.com ↗
2021-03-09
Immutep S.A.S.
Immutep Secures Second United States Patent Grant For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor immutep.com ↗
2021-01-26
Immutep S.A.S.
Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study immutep.com ↗
2020-12-28
Immutep S.A.S.
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor immutep.com ↗
2020-08-11
Immutep S.A.S.
Immutep Granted United States Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination immutep.com ↗
2020-05-06
Immutep S.A.S.
Immutep Granted Japanese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination immutep.com ↗
2019-08-21
Immutep S.A.S.
Immutep Granted European Patent for Eftilagimod Alpha in Cancer immutep.com ↗
2019-06-20
Immutep S.A.S.
Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy immutep.com ↗
2019-05-22
Immutep S.A.S.
Immutep Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunotherapy immutep.com ↗
2019-03-26
Immutep S.A.S.
Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast immutep.com ↗
2019-03-20
Immutep S.A.S.
Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer immutep.com ↗
2017-11-14
Immutep S.A.S.
Eftilagimod Alpha (LAG-3Ig or IMP321) Pre-IND Meeting with the FDA immutep.com ↗
2017-11-07
Immutep S.A.S.
New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting immutep.com ↗
Show 25 more releases